Alcohol
-
Register
- Non-Member - $39
- Regular Member - $29
- Retired - $29
- Early Career Physician - $29
- Resident - $19
- Student - $19
- Associate - $19
- ASAM Staff - Free!
- International Member - $29
- Emeritus Member - $29
- Provisional Member - $29
- Fellow Member - $29
- Honorary Member - $29
- CRT Member - $29
Alcohol
Recorded: Thursday, October 17, 2024 - Friday, October 18, 2024
On-Demand Session
Overview
According to 2023 national data, 10% of individuals ages 12 and older met criteria for an alcohol use disorder (AUD) in the past year. This indicates an urgent need for effective and innovative approaches to meet the needs of this large treatment population. This session will examine new research on AUD treatment, including spironolactone, psychedelics, GLP-1, and technology-assisted approaches.
This session is comprised of 4 presentations that deep dive into different aspects of the overall topic.
- Spironolactone in Alcohol Addiction: A Translational Approach
This session will review recent work conducted in animal models, including mice, rats, and non-human primates, as well as recent work in humans, including in people with alcohol use disorder, that has been conducted on (1) the relationship between aldosterone and alcohol drinking and dependence, and (2) the potential role of spironolactone in alcohol use disorder. - Psychedelics for the Treatment of Alcohol Use Disorder
The session will describe the results of completed trials of investigational psychedelic medications in the treatment to alcohol use disorder. Evidence for safety and efficacy will be evaluated, and possible mechanisms of action will be discussed based on currently available data. The prevention will also discuss possible next steps toward clinical use and safe and equitable dissemination of new treatments should they become available for clinical use. - Repurposing the Glucagon-Like Peptide-1 Receptor Agonist Semaglutide to Treat Alcohol Use Disorder
Anecdotal reports of the efficacy of semaglutide and other Glucagon-Like Peptide-1 (GLP-1) receptor agonists as medical therapies for obesity have garnered widespread public attention, engendering ethical debates and leading to worldwide drug shortages. This brief presentation will update participants about the National Institute on Drug Abuse Intramural Research Program's ongoing early phase clinical trial studying the exciting possibility of repurposing semaglutide to treat patients with alcohol use disorder. - Technology-Assisted Approaches to Facilitate Remotely Delivered Alcohol Use Disorder Treatment
This session will provide an overview of recent research that has involved remotely delivered alcohol use disorder treatment. Covered topics will include the key elements of treatment delivery that can be facilitated by technology, the types of devices and their features that have been useful for this research, and results from randomized clinical trials employing these techniques. Overall, results will demonstrate that technology-assisted approaches to alcohol use disorder treatment delivery can demonstrate high degrees of efficacy while overcoming some of the treatment-access barriers associated with in-person treatments.
These sessions are intended for experienced learners and are taught an intermediate or advanced level. The target audience includes:
- Addiction medicine specialists who are interested in the latest research in the field and its translation to clinical practice
- Physicians and other healthcare professionals who treat patients with addiction and seek an advanced level of knowledge
- Scientists, researchers, public health officials and advocates dedicated to the field of addiction medicine
This conference addresses all 6 ACGME Competencies.
Learning Objectives
At the end of the course, learners should be able to:
- Discuss the important, new, scientific breakthroughs in the prevention, diagnosis, and treatment of addiction.
- Critically evaluate new science and describe how it changes the current understanding of addiction and co-occurring medical or psychiatric disorders.
- Develop practical applications for integrating new and emerging science into practice.
- Identify gaps in the field of addiction medicine that future research can address.
- Create a network of colleagues and resources to support the learner's practice or form future research collaborations.
DEA Education Requirement
As an accredited organization named in Section 1263 of the Consolidated Appropriations Act of 2023, ASAM certifies that completion of this course meets 2 hours of the DEA requirement for 8 hours of education on substance use disorder(s).
Registration Rates
| ASAM Learner Type | Rate |
| ASAM Member | $29 |
| Non-Member | $39 |
| Associate Member | $19 |
| Resident Member* | $19 |
| Student Member* | $19 |
*Residents, Fellows-in-training, Interns, and Students must join ASAM to receive a discounted registration rate. Click here to become an ASAM member. National and Chapter membership dues apply. There is no charge for Students to become a Member, but verification of student status is required.
Membership Question? Call ASAM at 1.301.656.3920, email us, or view the ASAM website for more information.
Refunds & Cancellations
All ASAM eLearning Center refund requests must be made in writing to Education@ASAM.org within 90 days of purchase. Those requesting refunds for courses that are in progress will receive partial refunds or eLearning Center credit. Automatic full refunds will be made for any course with a live-course component that has been cancelled.
Registration Open: 11/01/2024 - 10/01/2027
User Access Closed: 11/01/2027
Instructions
- Click on the Contents tab to begin this activity.
- Click Complete Post Test to answer multiple choice questions. Participants will have 10 attempts to pass and must answer 4 out of 5 questions correctly.
- Click Complete Evaluation to provide valuable activity feedback. Scroll down on all questions as there may be answer options that expand past the size of the window.
- Click the button Claim Medical Credits in the box titled Claim Credits & Certificate. Choose the type of credit and click submit. Click the button View/Print Certificate to save or print your certificate. You can view/print your certificate at any time by visiting the ASAM eLearning Center, clicking Dashboard, and clicking Transcript/Achievements.
Need Assistance?
For assistance logging in, accessing activities, claiming credit, or for other questions or concerns, please check the FAQ page or e-mail Education@ASAM.org
ASAM is proud to offer eSSENTIAL Accessibility to ensure our website is accessible and functional for all our learners while providing free assistive technology for people with the widest possible range of abilities.
Lorenzo Leggio
MD. PhD, MSc
Dr. Lorenzo Leggio serves as the Chief of the joint NIAAA/NIDA Section on Clinical Psychoneuroendocrinology and Neuropsychopharmacology. He received his M.D. and Ph.D. from the Catholic University of Rome, where he also completed residency and Board Certification in Internal Medicine. He received a Masters in Alcoholism from the University of Florence. He was a postdoctoral research associate in Psychiatry and Human Behavior at Brown University. In 2010, he became Assistant Professor at the Brown University Center for Alcohol and Addiction Studies (CAAS). Dr. Leggio's clinical research has been primarily focused on the treatment of alcoholism, with an emphasis on the role of feeding-related and GABAergic pathways; and on the medical consequences of alcoholism, with an emphasis on alcoholic liver disease. While at Brown, he received funding from NIH and various foundations. In 2012, Dr. Leggio joined NIAAA and NIDA as a joint Clinical Investigator and Section Chief. He is licensed and credentialed as Senior Attending Medical Staff at the NIH Clinical Center. Dr. Leggio also serves as the Associate Director for Clinical Research for the NIDA IRP Medication Development Program. Additionally, he is an Adjunct Associate Professor at the Brown University CAAS. Dr. Leggio's lab has pioneered clinical research on the role of neuroendocrine signaling in alcoholism. He has authored or co-authored over 100 peer-reviewed manuscripts and has served as reviewer for NIH study sections and other U.S. and international funding agencies. He has served as consultant for FDA advisory panels, and on the editorial boards of addiction-related journals. He has served as Chair (Clinical) of the 2016 Research Society on Alcoholism (RSA) Program Committee. Among other awards, he received the 2008 ESBRA Nordmann Award, the 2015 NIAAA Clinical Service Award, the 2016 NIAAA Mentoring Award, and the 2016 RSA Early Career Investigator Award
No Relevant Financial Disclosures
Michael P. Bogenschutz, MD
Director
NYU Langone Center for Psychedelic Medicine
Dr. Bogenschutz is a Professor of Psychiatry at NYU Grossman School of Medicine and director of the NYU Langone Center for Psychedelic Medicine. He is an addiction psychiatrist with over 20 years of experience conducting NIH-funded research on pharmacological and behavioral treatments for addictions and co-occurring psychiatric disorders. Prior to joining the faculty at NYU Grossman School of Medicine in 2015, he was Vice-chair for Addiction Psychiatry at the University of New Mexico, where he established and directed an addiction psychiatry fellowship and for 10 years served as the PI of the Southwest Node of the NIDA Clinical Trials Network. Over the past decade he has investigated the therapeutic potential of serotonergic psychedelic drugs such as psilocybin and MDMA. He has completed two trials of psilocybin-assisted treatment for alcohol use disorder, and currently site PI for a 3-site NIDA-funded trial of psilocybin in the treatment of tobacco use disorder. He is also engaged in NIAAA-funded research on non-psychedelic pharmacotherapies, focusing on efficacy as well neural mechanisms and the use of machine learning strategies to identify likely responders.
No relevant financial disclosures
Stephanie T. Weiss
MD, PhD
Stephanie T. Weiss, MD PhD is the staff Research Physician serving the Translational Addiction Medicine Branch (TAMB) of the NIDA Intramural Research Program. After earning a Ph.D. in pharmaceutical chemistry, Dr. Weiss received her medical degree from Cleveland Clinic Lerner College of Medicine. She is board certified in emergency medicine and medical toxicology, a subspecialty that cares for patients with poisonings, environmental exposures, and overdoses. She subsequently completed a second fellowship in addiction medicine research and was selected to participate in the Boston University Research in Addiction Medicine Scholars Program prior to joining NIDA. Dr. Weiss assumes responsibility for providing optimal, safe, and ethical care to study participants and clinical support toward the TAMB mission conducting inpatient and outpatient proof-of-concept human laboratory studies. Her research interests include novel psychoactive substances, medication misuse, and improving interpretation of urine drug testing.
No relevant financial disclosures.
Mikhail N. Koffarnus, PhD
Associate Professor
University of Kentucky
Mikhail Koffarnus, PhD, is an Associate Professor and Vice Chair for Research in the Department of Family and Community Medicine at the University of Kentucky College of Medicine. He received his BA in Psychology from the University of Wisconsin - Eau Claire and his MS and PhD in Biopsychology at the University of Michigan. He also completed a pre-doctoral fellowship at the National Institute on Drug Abuse and a post-doctoral fellowship in the Behavioral Pharmacology Research Unit at Johns Hopkins University. He currently sits on the editorial board of two academic journals and is a Fellow of the American Psychological Association. He was also recently elected President of the Society for Psychopharmacology and Substance Use (American Psychological Association Division 28) to take effect in 2025. His research focuses on understanding decision-making and valuation processes that perpetuate substance use, as well as the translation of that understanding to applied endpoints such as tobacco regulatory policy and substance use treatment methodologies. Current projects are investigating mobile health approaches to remote delivery of behavioral alcohol use disorder treatment and estimating the impact of proposed tobacco product regulations in Appalachian Kentucky as a function of rurality.
No relevant financial disclosures
Credits & Disclosures
Joint Accreditation Statement
In support of improving patient care, the American Society of Addiction Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credits Available
- Physicians: 2 Credit(s)
- Nurses & NPs: 2 Nursing Contact Hour(s)
- Pharmacology Hour(s): 1 Hour(s)
- PAs: 2 Credit(s)
- Pharmacists: 2 Credit(s)
- Interprofessional Continuing Education: 2 Credit(s)
- Certified Counselors: NBCC Contact Hours Not offered
Note for pharmacists: Not all courses offer CPE Credit. For courses that do offer CPE Credit, pharmacists must claim credit and provide their eProfile ID and Birthdate via the Pharmacist Survey within 30 days of completing the activity. ASAM will not report CPE Credits claimed 30+ days after activity completion to ACPE. ASAM will not report CPE Credits without accurate and complete information. Courses offering CPE Credit will indicate the amount of credit available for pharmacists on the Credits & Disclosure Tab. For any questions or concerns, please e-mail Education@ASAM.org
Maintenance of Certification (MOC)/Continuing Certification Program (CCP)
This activity is designed to meet the requirements for MOC/CCP for several primary physician boards and for state licensing CME requirements. MOC Credit is only reported and designated for ABA, ABP, ABIM, and ABS. By completing the online credit application and evaluation, the learner permits ASAM to report credits to the appropriate Board. Learn more.
- ABA MOCA 2.0®*: 2 Lifelong Learning
- ABIM MOC Points: 2 Medical Knowledge
- ABP MOC: 2 Lifelong Learning & Self-Assessment
- ABS Continuing Certification: 2 Accredited CME | 2 Self-Assessment
Additionally, this activity has been designed to satisfy the requirements of the following primary physician board certification requirements. Please confirm with your individual Board.
- American Board of Addiction Medicine (ABAM)
- American Board of Preventative Medicine (ABPM)
- American Board of Psychiatry and Neurology (ABPN)
- Royal College of Physicians and Surgeons of Canada (RCPSC)
Certificates for other professions
All participants may request a certificate of participation upon completion of the activity and an online evaluation confirming their participation. Learners are strongly advised to contact their professional licensing board or professional association to confirm this certificate will be accepted as evidence supporting continuing education requirements.
California Association for Drug/Alcohol Educators (CAADE)
This educational program is approved by CAADE: #CP40 999 1225.
California Association of DUI Treatment Centers (CADTP)
This educational program is approved by CADTP: #205.
California Consortium of Addiction Programs and Professionals (CCAPP)
This educational program is approved by CCAPP: #OS-20-330-1224.
MOCA 2.0® is a trademark of the American board of Anesthesiology®. This activity contributes to the patient safety CME requirement for Part II: Lifelong Learning and Self-Assessment of the American board of Anesthesiology's (ABA) redesigned Maintenance of Certification in Anesthesiology Program® (MOCA®), known as MOCA 2.0®. Please consult the ABA website, https://www.theaba.org/, for a list of all MOCA 2.0 requirements.
Disclosure Information
In accordance with the disclosure policies of ASAM and Joint Accreditation, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all accredited continuing education activities. These policies include identifying and mitigating all relevant financial relationships with ineligible companies for those involved in the creation and dissemination of accredited continuing education.
See the attached pdf for a list of disclosures.
Key:
Complete
Next
Failed
Available
Locked